Redeye: Lytix Biopharma (Q3 Review) - Positive Clinical Readouts
19 november, 2025
19 november, 2025
Redeye comments on Lytix' third quarter report 2025. After the quarter, positive results were presented in both main programmes. Lytix presented a strong interim readout in NeoLIPA, the study in neoadjuvant melanoma, while Verrica disclosed immune activation in biopsies of BCC.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
19 november, 2025
Redeye comments on Lytix' third quarter report 2025. After the quarter, positive results were presented in both main programmes. Lytix presented a strong interim readout in NeoLIPA, the study in neoadjuvant melanoma, while Verrica disclosed immune activation in biopsies of BCC.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
Placera listar
Analyser
Förvaltarbyten

Inflationen


Bostadspriser
Placera listar
Analyser
Förvaltarbyten

Inflationen


Bostadspriser
1 DAG %
Senast




Igår, 07:57
Lista: Aktierna som har stigit mest
Bolåneräntor
6 februari, 19:42
Bankerna har 125 miljarder skäl att älska bolånerabatter
OMX Stockholm 30
1 DAG %
Senast
3 120,45